Bayer: fast track designation for asundexian
(CercleFinance.com) - Bayer today announced that the US FDA has granted Fast Track designation to its investigational drug asundexian as a potential treatment to prevent stroke and systemic embolism in people with atrial fibrillation.
This news follows the first Fast Track designation of asundexian by the US FDA for the prevention of stroke in patients with non-cardioembolic ischaemic stroke, which was granted in 2022.
Asundexian is an investigational agent that has not been approved for use by any health authority in any country. It is currently being evaluated as a potential once-daily oral factor XIa (FXIa) inhibitor for the prevention of thrombosis.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
This news follows the first Fast Track designation of asundexian by the US FDA for the prevention of stroke in patients with non-cardioembolic ischaemic stroke, which was granted in 2022.
Asundexian is an investigational agent that has not been approved for use by any health authority in any country. It is currently being evaluated as a potential once-daily oral factor XIa (FXIa) inhibitor for the prevention of thrombosis.
Copyright (c) 2023 CercleFinance.com. All rights reserved.